Alfa Cytology, a provider of biomedical research support services, announced the enhancement of its radiopharmaceutical development service portfolio by integrating custom radiolabeling for antibody-drug conjugates (ADCs) and targeted radiopharmaceuticals with Radiopharmaceutical Physicochemical Characterization CRO services. This integration aims to offer biotechnology and pharmaceutical companies, as well as scientific research institutions, a more comprehensive approach to radiopharmaceutical development.
Radiopharmaceuticals have become a cornerstone of precision medicine, enabling applications from cancer diagnosis to targeted therapy. The increasing number of research projects utilizing radiolabeling technologies for pharmacokinetic studies, biodistribution analysis, and molecular imaging has driven demand for advanced development capabilities. However, the successful completion of radiolabeling is only one step; key attributes such as radiochemical purity, stability, lipophilicity, and target-binding capability require thorough evaluation. Alfa Cytology's enhanced platform addresses this need by providing coordinated support from radiolabeling to critical quality attribute assessment.
The company's custom radiolabeling for ADCs and targeted radiopharmaceuticals services support the labeling of antibodies, ADCs, peptide therapeutics, small molecules, and other targeted compounds using various radionuclides for diagnostic and therapeutic applications. These services facilitate pharmacokinetic studies, biodistribution analysis, molecular imaging, and radiopharmaceutical development.
Simultaneously, the physicochemical characterization CRO services analyze key parameters including radiochemical purity, stability, lipophilicity (LogP/LogD), and immunoreactivity. Systematic characterization helps research teams evaluate candidate properties and generate reliable data for subsequent studies.
"The demand for high-quality radiolabeling and physicochemical characterization data continues to grow as radiopharmaceutical development advances," said a spokesperson for Alfa Cytology. "By integrating our technical capabilities, we aim to provide customers with more efficient research support and help advance the development of innovative radiopharmaceuticals and targeted therapies."
This enhancement comes as the radiopharmaceutical and ADC fields rapidly evolve, with increasing focus on targeted therapies. By covering key research activities from radiolabeling to critical quality attribute assessment, Alfa Cytology aims to help customers improve development efficiency and reduce uncertainty throughout the research process.
